Humira is a Biologic. These drugs are designed to target a specific area with your immune system. In the case of Humira , it is an TNF inhibitor. The goal unlike DMARD's (disease modifying anti rheumatic'), is to shut down only part of immune system rather than your entire immune system. This can reduce risk of infection. Many doctors will combine both DMARD and Biologic for moderate to severe RD. They are expensive because pharmaceutical companies cornered the market. Unlike other generic drugs , Biologics cannot be duplicated in a lab. Or at least not until recently. Now there is Biosimilars. These are still new to the market. These drugs have worked miraculously for many patients however, the goal is to find a combination that works for you. Be aware of the side effects and report them to your doctor.

https://www.humira.com/humira-complete/cost-and... Humira's AbbVie does offer a copay assistance program which I am currently using in tandem with my insurance which significantly reduces my out of pocket expense. Depending what sort of insurance you have, you may qualify for the same program. Call them to see!

In May of 2021, the makers of a widely-used medication in the U.S. and in Europe for rheumatoid arthritis were accused of raising prices in the U.S., but cutting the price overseas.

In May of this year, the makers of a widely-used medication in the U.S. and in Europe for rheumatoid arthritis were accused of raising prices in the U.S., but cutting the price overseas.

Apparently, reports say, the makers of the medication exploited patents to keep competitors out of the market while increasing the price of the widely-used injectable medication for rheumatoid arthritis to around $77,000 per year. That's $77,000 for a person to pay for medication that helps them live.

The company, makers of the injectable medication, sought hundreds of patents for one medication-a practice that isn't illegal, but does create barriers to competition. The cost of one patent is prohibitively expensive and time-consuming, but for large manufacturers with an eye on a cash market, the practice is simply protecting the cash flow.

This specific injectable medication is the top seller in the world reaching more than $21B in 2021, but the price makes it inaccessible to many people with the very condition it was created to treat.

The price of the medication in the U.S. makes the medication less accessible in the U.S. to Americans *redundant on purpose* with rheumatoid arthritis. And to put an even finer point on it: the price of the most prescribed medication for rheumatoid arthritis is completely inaccessible to people without insurance due to the cost. Why? Because the company simultaneously LOWERED prices abroad in order to make the medication more attractive under single-payer systems while they RAISED prices in the U.S. In other words, they raised the price of the medication because they can. Because insurers will pay it. Because there is no competition. Because they kept out the competition with a mountain of patents. Because they can.

Humira is made by Abbvie and they have an assistance program for payment.

Contact abbvie. I get assistance